|1.||Cortes, Jorge: 10 articles (01/2015 - 04/2002)|
|2.||Jin, Jie: 8 articles (10/2013 - 07/2007)|
|3.||Wetzler, Meir: 6 articles (05/2015 - 01/2011)|
|4.||Kantarjian, H M: 5 articles (01/2015 - 10/2000)|
|5.||Kantarjian, Hagop: 5 articles (01/2015 - 01/2007)|
|6.||Tong, Yin: 5 articles (01/2014 - 01/2008)|
|7.||Qian, Wen-bin: 5 articles (10/2013 - 11/2009)|
|8.||Quintás-Cardama, Alfonso: 5 articles (10/2013 - 01/2007)|
|9.||Kantarjian, Hagop M: 4 articles (05/2015 - 04/2002)|
|10.||Baccarani, Michele: 4 articles (05/2015 - 07/2013)|
|1.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
06/15/1999 - "Homoharringtonine (HHT) is a novel plant alkaloid that produced a complete hematologic remission (CHR) in 72% of patients with late chronic phase chronic myelogenous leukemia (CML). "
07/01/2013 - "Omacetaxine mepesuccinate: a new treatment option for patients with chronic myelogenous leukemia."
07/01/2015 - "The objective of this study was to determine the changes in protein profiles of K562 chronic myeloid leukemia (CML) cells in response to Homoharringtonine (HHT). "
05/01/2012 - "This study investigated the effect of homoharringtonine (HHT) on bone marrow CD34 + CD117 + cells in patients with chronic myelogenous leukemia (CML). "
01/01/2011 - "Omacetaxine mepesuccinate was originally identified more than 35 years ago and initial studies in chronic myeloid leukemia (CML) showed promising activity. "
|2.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
03/01/2012 - "High-dose homoharringtonine does not clearly increase the complete remission rate of elderly patients with acute myeloid leukemia. "
11/01/1992 - "Homoharringtonine is safe and effective for patients with acute myelogenous leukemia."
08/01/2001 - "A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study."
06/20/2015 - "Here we identify a small molecule, homoharringtonine (HHT), that antagonizes p-eIF4E function and eradicates acute myeloid leukemia (AML) expressing high level of p-eIF4E in vitro and in vivo. "
01/01/2015 - "The present meta-analysis provides an overview on the effectiveness of homoharringtonine (HHT) combination regimens to treat acute myeloid leukemia (AML). "
|3.||Acute Promyelocytic Leukemia
11/01/2011 - "[Outcome of acute promyelocytic leukemia with homoharringtonine (HHT) and ATRA]."
11/01/2011 - "To assess complete remission (CR), the overall survival (OS), event-free survival (EFS) and adverse events of newly diagnosed acute promyelocytic leukemia (APL) with homoharringtonine (HHT) plus ATRA, to evaluate the therapeutic effect by comparing HHT plus ATRA with daunorubicin plus ATRA as induction regimen (HA with DA as post-remission regimen). "
03/01/2015 - "Long-term follow-up of homoharringtonine plus all-trans retinoic acid-based induction and consolidation therapy in newly diagnosed acute promyelocytic leukemia."
02/01/2013 - "[Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia]."
03/01/2015 - "We conducted a retrospective study to evaluate the efficacy of combining homoharringtonine (HHT) with all-trans-retinoic acid (ATRA)-based induction therapy, followed by three courses of consolidation chemotherapy and 2-year sequential maintenance therapy in acute promyelocytic leukemia (APL). "
07/01/2015 - "A comparative proteomic study of Homoharringtonine-induced apoptosis in leukemia K562 cells."
06/01/2009 - "To study the resistant related molecules of human leukemia drug resistant K562 cells (K562/HHT) induced by homoharringtonine (HHT). "
07/01/2008 - "This study was to explore the influence of RNA interference (RNAi) targeting HIF-1alpha on sensitivity of human chronic myelogeneous leukemia (CML) K562 cells towards homoharringtonine (HHT). "
05/01/2008 - "In preclinical studies, omacetaxine mepesuccinate induced apoptosis in leukemia cell lines. "
01/01/2006 - "Homoharringtonine (HHT), first isolated from the Chinese evergreen Cephalotaxus Harringtonia, has been shown inhibiting activity in leukemia in initial studies in China and in later studies in the US, but the detailed mechanism of action is still unclear. "
01/01/2013 - "Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors."
03/01/1986 - "Five phase II trials of the antitumor agent homoharringtonine were conducted in 80 patients who had advanced solid tumors. "
09/01/1984 - "For phase II studies of homoharringtonine in solid tumors, a daily dose of 3 mg/m2 for 5 days in patients with extensive prior treatment and 4 mg/m2/day for 5 days in patients with good bone marrow reserve will be utilized. "
07/01/1983 - "Homoharringtonine (HHT) has substantial cytotoxic activity against cell lines of experimental tumors. "
02/01/1983 - "Activity of two phase I drugs, homoharringtonine and tricyclic nucleotide, against surgical explants of human tumors in the 6-day subrenal capsule assay."
|4.||Granulocyte Colony-Stimulating Factor (G-CSF)
|8.||Tretinoin (Retinoic Acid)
|1.||Drug Therapy (Chemotherapy)